<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02894021</url>
  </required_header>
  <id_info>
    <org_study_id>PI2013_843_0001</org_study_id>
    <nct_id>NCT02894021</nct_id>
  </id_info>
  <brief_title>PREvention of Post-mastectomy LYMphoceles by PAdding</brief_title>
  <acronym>PRELYMCA</acronym>
  <official_title>PREvention of Post-mastectomy LYMphoceles by PAdding. A Randomized Prospective Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <brief_summary>
    <textblock>
      Lymphoceles, or seromas, are the most frequent complication following mastectomy and are&#xD;
      associated or not with axillary dissection occurring in 10 to 90% of cases. It is defined as&#xD;
      the presence of a palpable post operative serous accumulation that is bothersome for the&#xD;
      patient and requires a puncture and drainage or even several repeated punctures. The presence&#xD;
      of seromas is therefore associated with discomfort and pain. Seromas could also be&#xD;
      responsible for increased morbidity due to complications such as infection, suture&#xD;
      separating, lymphedema, prolonged of hospital stay, or a delay in initiation of adjunct&#xD;
      treatment (e.g. chemotherapy, radiotherapy). Some risk factors have been identified, such as&#xD;
      obesity, increased post operative drainage of J1 to J3, and arterial hypertension.&#xD;
&#xD;
      Different measures have demonstrated the benefits of limiting axillary lymphoceles after&#xD;
      dissection : placement of a drain, padding and delay in shoulder mobility.&#xD;
&#xD;
      Studies have shown that axillary padding decreases lymphocele development and shortens the&#xD;
      length of hospital stay. Some studies based on padding of the mastectomy site also have shown&#xD;
      a decrease in post operative seromas; however no study has been done on the usefulness of&#xD;
      padding in the mastectomy site alone because they include both padding and a drain or padding&#xD;
      of the axillary area.&#xD;
&#xD;
      The padding technique the investigators employ is performed at the donor site in breast&#xD;
      reconstruction by latissimus dorsi muscle flap, demonstrating a reduction in the rate of&#xD;
      seromas.&#xD;
&#xD;
      In this study, the classic technique will be compared to padding in the mastectomy site with&#xD;
      short drainage (48h).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative lymphoceles</measure>
    <time_frame>Day 15</time_frame>
    <description>presence or absence of postoperative lymphoceles</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Mastectomy</condition>
  <arm_group>
    <arm_group_label>classic closure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>padding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>areas of padding and stiching between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>classic closure</intervention_name>
    <description>mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration</description>
    <arm_group_label>classic closure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>padding</intervention_name>
    <description>areas of padding and running sutures between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h</description>
    <arm_group_label>padding</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Female gender&#xD;
&#xD;
          -  Patients with infiltrating or in situ breast cancer&#xD;
&#xD;
          -  Indication of surgical treatment by mastectomy&#xD;
&#xD;
          -  Patient providing written informed consent&#xD;
&#xD;
          -  Patient with health insurance coverage&#xD;
&#xD;
          -  Ability to provide voluntary written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Informed consent cannot be obtain&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients undergoing immediate breast reconstruction&#xD;
&#xD;
          -  Patients with cancer untreatable by mastectomy, non curative mastectomy: partial&#xD;
             mastectomies, preventive mastectomies (BRCA genetic mutations)&#xD;
&#xD;
          -  Patients under legal protection or unable to come to a center&#xD;
&#xD;
          -  Patients unable to express voluntary consent&#xD;
&#xD;
          -  Patients receiving post operative anticoagulants or platelet antiaggregants&#xD;
&#xD;
          -  Patients requiring postoperative anticoagulants&#xD;
&#xD;
          -  Bilateral mastectomy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mohamed AIT AMER MEZIANE, PhD</last_name>
    <phone>+33 3 22 66 85 23</phone>
    <email>AitAmerMeziane.Mohamed@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed AIT AMER MEZIANE, PhD</last_name>
      <phone>+33 3 22 66 85 23</phone>
      <email>AitAmerMeziane.Mohamed@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Compiègne</name>
      <address>
        <city>Compiegne</city>
        <zip>60321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna MYCHALUK, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Soissons</name>
      <address>
        <city>Soissons</city>
        <zip>02209</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal ABBOUD, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 5, 2016</study_first_submitted>
  <study_first_submitted_qc>September 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>September 5, 2016</last_update_submitted>
  <last_update_submitted_qc>September 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>padding</keyword>
  <keyword>lymphoceles</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphocele</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

